* Biodesix Inc is expected to show a rise in quarterly revenue when it reports results on November 1 for the period ending September 30 2024
* The Louisville Colorado-based company is expected to report a 38.0% increase in revenue to $18.611 million from $13.49 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Biodesix Inc is for a loss of 7 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Biodesix Inc is $3.00, above its last closing price of $1.65.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.09 -0.09 -0.08 Beat 13
Mar. 31 2024 -0.14 -0.14 -0.14 Met 2.3
Dec. 31 2023 -0.10 -0.11 -0.10 Beat 9.1
Sep. 30 2023 -0.15 -0.15 -0.14 Beat 6.7
Jun. -0.22 -0.21 -0.17 Beat 17.7
30 2023
Mar. 31 2023 -0.23 -0.24 -0.24 Met -1.4
Dec. 31 2022 -0.21 -0.28 -0.35 Missed -26.1
Sep. 30 2022 -0.33 -0.33 -0.34 Missed -3.8
This summary was machine generated October 30 at 13:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。